Gold-conjugated green tea nanoparticles for enhanced anti-tumor activities and hepatoprotection - synthesis, characterization and in vitro evaluation

Journal of Nutritional Biochemistry

Volumn 26, Issue 11, 2015, Pages 1283-1297

  Mukherjee, Sudeshna ^a   Ghosh, Sayan ^a   Das, Dipesh Kr ^a   Chakraborty, Priyanka ^a   Choudhury, Sreetama ^a   Gupta, Payal ^a   Adhikary, Arghya ^a   Dey, Sanjit ^a   Chattopadhyay, Sreya ^a  

^a UNIVERSITY OF CALCUTTA   (India)

Author keywords

Apoptosis; EGCG; Green tea; Hepatotoxicity; Nanochemoprevention; NF B; Nrf2

Indexed keywords

CASPASE 3; EPIGALLOCATECHIN GALLATE; GLUTATHIONE; GOLD NANOPARTICLE; GREEN TEA EXTRACT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOCONJUGATE; NITRATE REDUCTASE [NAD(P)H]; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CATECHIN; GOLD; NANOPARTICLE; TEA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DAMAGE; DEFENSE MECHANISM; DOWN REGULATION; EHRLICH ASCITES TUMOR CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER PROTECTION; MALE; MCF 7 CELL LINE; MOUSE; NANOFABRICATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PROTEIN PHOSPHORYLATION; TEA; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; LIVER; MCF-7 CELL LINE; METABOLISM; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CATECHIN; DRUG EVALUATION, PRECLINICAL; GOLD; HEPATOCYTES; HUMANS; LIVER; MALE; MCF-7 CELLS; MICE; NANOPARTICLES; TEA;

EID: 84946480991     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.06.003     Document Type: Article

References (80)

1. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010, 5:597-615.
2. Sak K. Chemotherapy and dietary phytochemical agents. Chemother Res Pract 2012, 2012:282570-282581.
3. Forester S.C., Lambert J.D. Antioxidant effects of green tea. Mol Nutr Food Res 2011, 55:844-854.
4. Khan N., Adhami V.M., Mukhtar H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer 2009, 61:836-841.
5. Kanwar J., Taskeen M., Mohammad I., Huo C., Chan T.H., Dou Q.P. Recent advances on tea polyphenols. Front Biosci (Elite Ed) 2012, 4:111-131.
6. Schramm L. Going green: the role of the green Tea component EGCG in chemoprevention. J Carcinog Mutagen 2013, 4:1000142.
7. Yang G., Zheng W., Xiang Y.B., Gao J., Li H.L., Zhang X., et al. Green tea consumption and colorectal cancer risk: A report from the Shanghai Men's Health Study. Carcinogenesis 2011, 32:1684-1688.
8. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66:1234-1240.
9. Inoue M., Tajima K., Mizutani M., Iwata H., Iwase T., Miura S., et al. Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Jpn Cancer Lett 2001, 167:175-182.
10. Steele V.E., Kelloff G.J., Balentine D., Boone C.W., Mehta R., Bagheri D., et al. Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis 2000, 21:63-67.
11. Yang C.S., Maliakal P., Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002, 42:25-54.
12. Jatoi A., Ellison N., Burch P.A., Sloan J.A., Dakhil S.R., Novotny P., et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97:1442-1446.
13. Hamajima N., Tajima K., Tominaga S., Matsuura M., Kuwabara M., Obuma K. Tea polyphenol intake and changes in serum pepsinogen levels. Jpn J Cancer Res 1999, 90:136-143.
14. Wang L.D., Zhou Q., Feng C.W., Liu B., Qi Y.J., Zhang Y.R., et al. Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer. Gan To Kagaku Ryoho 2002, 29:159-172.
15. Pae M., Ren Z., Meydani M., Shang Fu., Smith D., Meydani S.N., et al. Dietary supplementation with high dose of epigallocatechin-3-gallate promotes inflammatory response in mice. J Nutr Biochem 2012, 23:526-531.
16. Galati G., Lin A., Sultan A.M., O'Brien P.J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 2006, 40:570-580.
17. Lambert J.D., Kennett M.J., Sang S., Reuhl K.R., Ju J., Yang C.S. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 2010, 48:409-416.
18. Kale A., Gawande S., Kotwal S., Netke S., Roomi W., Ivanov V., et al. Studies on the effects of oral administration of nutrient mixture, quercetin and red onions on the bioavailability of epigallocatechin gallate from green tea extract. Phytother Res 2010, 24(Suppl. 1):S48-S55.
19. Landis-Piwowar K.R., Huo C., Chen D., Milacic V., Shi G., Chan T.H., et al. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007, 67(9):4303-4310.
20. Dube A., Nicolazzo J.A., Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci 2010, 41(2):219-225.
21. Lambert J.D., Lee M.J., Lu H., Meng X., Hong J.J., Seril D.N., et al. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 2003, 133(12):4172-4177.
22. Cai Y., Anavy N.D., Chow H.S.S. Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats. Drug Metab Dispos 2002, 30:1246-1249.
23. Kattamuri V., Katti K., Bhaskaran S., Boote E.J., Casteel S.W., Fent G.M., et al. Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: in vivo pharmacokinetics and X-ray-contrast-imaging studies. Small 2007, 3:333-341.
24. Cai W., Gao T., Hong H., Sun J. Applications of gold nanotechnology in cancer nanotechnology. Nanotechnol Sci Appl 2008, 1:17-32.
25. Siddiqui I.A., Mukhtar H. Nanochemoprevention by bioactive food components: a perspective. Pharm Res 2010, 27:1054-1060.
26. Siddiqui I.A., Adhami V.M., Bharali D.J., Hafeez B.B., Asim M., Khwaja S.I., et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009, 69:1712-1716.
27. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bio-availability in vivo. Biochem Pharmacol 2010, 79:330-338.
28. Nune S.K., Chanda N., Shukla R., Katti K., Kulkarni R.R., Thilakavathy S., et al. Green nanotechnology from tea: phytochemicals in tea as building blocks for production of biocompatible gold nanoparticles. J Mater Chem 2009, 19:2912-2920.
29. El-Beshbishy H.A. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol 2005, 5:563-570.
30. Taga M.S., Miller E.E., Pratt D.E. Chia seeds as a source of natural lipid antioxidant. J Am Oil Chem Soc 1984, 61:928-931.
31. Pal S., Saha C., Dey S.K. Studies on black tea (Camellia sinensis) extract as a potential antioxidant and a probable radioprotector. Radiat Environ Biophys 2013, 52:269-278.
32. Kaur G., Jabbar Z., Athar M., Alam M.A. Punica granatum (pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe-NTA induced hepatotoxicity in mice. Food Chem Toxicol 2006, 44:984-993.
33. Oyaizu M. Studies on products of browning reaction prepared from glucosamine. Jpn J Nutr 1986, 44:307-315.
34. Yen G., Chen H. Antioxidant activity of various tea extract in relation to their antimutagenicity. J Agric Food Chem 1995, 43:27-32.
35. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S. Analysis of nitrate, nitrite, and [15 N] nitrate in biological fluids. Anal Biochem 1982, 126:131-138.
36. Bhattacharyya A., Choudhuri T., Pal S., Chattopadhyay S., Datta G.K., Das T., et al. Apoptogenic effects of black tea on Ehrlich's ascites carcinoma cell. Carcinogenesis 2003, 24:75-80.
37. Bhattacharya S., Ahir M., Patra P., Mukherjee S., Ghosh S., Mazumdar M., et al. PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials 2015, 51:91-107.
38. Manna K., Khan A., Das D.K., Kesh S.B., Das U., Ghosh S., et al. Protective effect of coconut water concentrate and its active component shikimic acid against hydroperoxide mediated oxidative stress through suppression of NF-κB and activation of Nrf2 pathway. J Enthnopharmacol 2014, 155:132-146.
39. Mukherjee S., Ghosh S., Choudhury S., Adhikary A., Manna K., Dey S., et al. Pomegranate reverses methotrexate-induced oxidative stress and apoptosis in hepatocytes by modulating Nrf2 NF-κB pathways. J Nutr Biochem 2013, 24:2040-2050.
40. He M., Zhao Z., Yin L., Tang C., Yin C. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm 2009, 373:165-175.
41. Kim J., Yoon T., Yu K., Noh M.I., Woo M., Kim B., et al. Cellular uptake of magnetic nanoparticle is mediated through energy-dependent endocytosis in A549 cells. J Vet Sci 2004, 7:321-326.
42. Mosmann T. Rapid colorimetric assay for cellular growth & survival: application of proliferation & cytotoxicity assay. J Immunol Methods 1983, 65:55-63.
43. Khan N., Afaq F., Kweon M.H., Kim K.M., Mukhtar H. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary tumors in mice. Cancer Res 2007, 67:3475-3482.
44. Lowry O.J., Rosebrough N.J., Farr A.L., Randall R.L. Protein measurement with folin-phenol reagent. J Biol Chem 1951, 193:265-275.
45. Wright J.R., Colby H.D., Miles P.R. Cytosolic factors which affect microsomal lipid peroxidation in lung and liver. Arch Biochem Biophys 1981, 206:296-304.
46. Jollow D.J., Mitchell J.R., Zampaglione N., Gillete J.R. Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzeneoxide as the hepatotoxic intermediate. Pharmacology 1974, 11:151-169.
47. Claiborne A. Catalase activity. CRC handbook of methods for oxygen radical research 1985, 283-284. CRC Press Boca Raton, FL, USA. R.A. Greenwald (Ed.).
48. Marklund S.L. Superoxide dismutase isoenzyme in tissues and plasma from New Zealand black mice, nude mice and normal BALB/C mice. Mutat Res 1985, 148:129-134.
49. Carraway M.S., Ghio A.J., Carter J.D., Piantadosi C.A. Expression of heme oxygenase 1 in lungs in chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2000, 278:L806-L812.
50. De Haan L.H., Boerboom A.M., Rietjens I.M., van Capelle D., De Ruijter A.J., Jaiswal A.K., et al. A physiological threshold for protection against menadione toxicity by human NAD(P)H:quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells. Biochem Pharmacol 2002, 64:1597-1603.
51. Tobon-Velasco J.C., Vazquez-Victoro G., Macias-Silva M., Cuevas E., Ali S.F., Maldonado P.D., et al. S-allyl cysteine protects against 6-hydroxydopamine-induced neurotoxicity in the rat striatum: involvement of Nrf2 transcription factor activation and modulation of signaling kinase cascades. Free Radic Biol Med 2012, 53:1024-1040.
52. Clerkin J.S., Naughton R., Quiney C., Cotter T.G. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 2008, 266:30-36.
53. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005, 10:1881-1896.
54. Bhattacharyya A., Mandal D., Lahiry L., Bhattacharyya S., Chattopadhyay S., Ghosh U.K., et al. Black tea-induced amelioration of hepatic oxidative stress through antioxidative acitivity in EAC-bearing mice. J Environ Pathol Toxicol Oncol 2007, 26:245-254.
55. Agbedana E.O., Ebesunum M.O. Abnormal serum alkaline and acid phosphatase isoenzymes in female breast cancer patients. Afr J Med Med Sci 1998, 27:65-69.
56. Korver K.D., Graham S.M., Hoffman H.T., McCulloch T., Funk G.F. Liver function studies in assessment of head and neck cancer patients. Head Neck 1995, 17:531-534.
57. Gilliam L.A., St.Clair D.K. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal 2011, 15:2543-2563.
58. Warden B.A., Smith L.S., Beecher G.R., Balentine D.A., Clevidence B.A. Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 2001, 131:1731-1737.
59. Maeta K., Noumura W., Takatsume Y., Izawa S., Inoue Y. Green tea polyphenols function as prooxidants to activate oxidative-stress-responsive transcription factors in yeasts. Appl Environ Microbiol 2007, 73:572-580.
60. Hoo C.M., Starostin N., West P., Mecartney M.L. A comparison of atomic force microscopy (AFM) and dynamic light scattering (DLS) methods to characterize nanoparticle size distributions. J Nanopart Res 2008, 10:89-96.
61. Honary S., Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems - a review (part 1). Trop J Pharm Res 2013, 12:255-264.
62. Legraand C., Bour J.M., Jacob C., Capiaumont J., Martial A., Marc A., et al. Lactate dehydrogenase (LDH) activity of the cultured eukaryotic cells as marker of the number of dead cells in the medium. J Biotechnol 1992, 25:231-243.
63. Manna A., Saha P., Sarkar A., Mukhopadhyay D., Bauri A.K., Kumar D., et al. Malabaricone-A induces a redox imbalance that mediates apoptosis in U937 cell line. PLoS One 2012, 7:e36938-e36949.
64. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007, 96:2181-2196.
65. Weydert C.J., Waugh T.A., Ritchie J.M., Iyer K.S., Smith J.L., Li L., et al. Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic Biol Med 2006, 41:226-237.
66. Pink J.J., Planchon S.M., Tagliarino C., Varnes M.E., Seigel D., Boothman D.A. NAD(P)H:Qiunone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 2000, 275:5416-5424.
67. Pal S., Dey S.K., Saha C. Inhibition of catalase by tea catechins in free and cellular state: A biophysical approach. PLoS One 2014, 9:e102460-e102469.
68. Fang J., Akaike T., Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis 2004, 9:27-35.
69. Fang J., Sawa T., Akaike T., Greish K., Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 2004, 109:1-8.
70. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., et al. Selective killing of oncogenically transformed cells through a ROS mediated mechanism by bphenylethyl isothiocyanate. Cancer Cell 2006, 10:421-452.
71. Na H.K., Surh Y.J. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med 2014, 67:353-365.
72. Bellezza I., Mierla A.S., Minelli A. Nrf2 and NF-κB and their concerted modulation in cancer pathogenesis and progression. Cancers 2010, 2:483-497.
73. Kweon M., Adhami V.M., Lee J., Mukhtar H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 2006, 281:33761-33772.
74. Tang X., Wang H., Fan L., Wu X., Xin A., Ren H., et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 2011, 50:1599-1609.
75. Trachootham D., Lu W., Ogasawara M.A., Valle N.R., Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008, 10:134-174.
76. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001, 480:243-268.
77. Basseres D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830.
78. Kabore A.F., Johnston J.B., Gibson S.B. Changes in the apoptotic and survival signalling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets 2004, 4:147-163.
79. Arrigo A.P. Gene expression and the thiol redox state. Free Radic Biol Med 1999, 27:936-944.
80. Yang L., Zheng X.L., Sun H., Zhong Y.J., Wang Q., He H.N., et al. Catalase suppression-mediated H2O2 accumulation in cancer cells by wogonin effectively blocks tumor necrosis factor-induced NF-kB activation and sensitizes apoptosis. Cancer Sci 2011, 102:870-876.